Clinical trials: Hepatocellular Carcinoma by BCLC Stage
NSCLC Stage IIIB, NSCLC Stage IV
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, Hepatocellular Carcinoma by BCLC Stage, Lung Cancer
- Trial name
- NCT03515252
- Testing
- Immune Killer Cells (IKC)
- Volunteers
- 20 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
HCC - Hepatocellular Carcinoma, Durvalumab
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), yet it shows limited efficacy with an ORR of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Durvalumab, Tremelimumab, Proton Radiotherapy
- Trial name
- Proton-STRIDE (NCT06999694)
- Testing
- Proton radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
This phase I trial studies the side effects and best dose of Chinese herbal formulation PHY906 when given together with sorafenib tosylate in treating patients with advanced liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Advanced Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma
- Trial name
- NCT01666756
- Testing
- Chinese herbal formulation PHY906, sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
HCC - Hepatocellular Carcinoma
Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma
This study aims to investigate the recurrence patterns and cost-effectiveness of robotic-assisted, laparoscopic, and open liver resections in patients with early-stage (BCLC 0/A) hepatocellular carcinoma.
- Trial name
- NCT06776185
- Testing
- Liver Surgery
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Chen Xiaoping
Hepatocellular Carcinoma
Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. For patients with intermediate HCC (BCLC stage B), transarterial chemoembolization (TACE) has been recommended as the standard therapy in many clinical…
- Trial name
- NCT02616926
- Testing
- Hepatic resection, TACE, RFA
- Where
- 3 sites in China
- Volunteers
- 538 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
This prospective, multicenter, phase II randomized controlled trial compares the efficacy and safety of SBRT combined with systemic therapy versus systemic therapy alone in BCLC stage C hepatocellular carcinoma (HCC).
- Trial name
- NCT07274774
- Testing
- Systemic therapy, Radiotherapy
- Where
- China
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, Lenvatinib
- Trial name
- NCT06632093
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 84 people
- Sponsor
- First Hospital of China Medical University
Hepatocellular Carcinoma
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
- Trial name
- NCT03851913
- Testing
- TAI
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or…
- Trial name
- NCT04483284
- Testing
- TACE combined with Camrelizumab, TACE plus Camrelizumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC), Emotional Distress
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
This study is a multicenter, prospective, observational clinical trial designed to evaluate the impact of baseline emotional status on the clinical outcomes of patients with BCLC stage B/C hepatocellular carcinoma undergoing HAIC…
- Conditions
- Hepatocellular Carcinoma (HCC), Emotional Distress, HAIC(Hepatic Artery Infusion Chemotherapy), Immunotherapy
- Trial name
- NCT07436845
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
This clinical trial studies positron emission tomography (PET)-computed tomography (CT) in determining the radiation dose delivered with radioactive spheres to patients with liver metastasis or primary liver or biliary cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02088775
- Testing
- PET scan, CT Scan, hepatic artery embolization
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Fox Chase Cancer Center
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
This early phase I trial evaluates the side effects of BO-112 and pembrolizumab and how well they work in treating patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C liver cancer.
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma
- Trial name
- NCT04777708
- Testing
- Nanoplexed Poly I:C BO-112, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC.
- Trial name
- NCT03780049
- Testing
- HAIC of FOLFOX, H101
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Metformin Plus Sorafenib for Advanced HCC
Metformin is a widely used oral drug for type 2 diabetes and its antitumor effects have got much more attentions recently. It has been shown that metformin exerts anti-cancer activities in several cancers, including primary liver…
- Trial name
- NCT02672488
- Testing
- Sorafenib, Metformin
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma by BCLC Stage
Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma
Anatomical liver resection was widely accepted as first line curative therapy for hepatocellular carcinoma. However, number of retrospective clinical studies showed no priority of anatomical resection for hepatocellular, compared…
- Trial name
- NCT03652896
- Testing
- anatomical liver resection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
- Trial name
- NCT03642561
- Testing
- radiotherapy ablation, transarterial chemoembolization(TACE)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Advanced Hepatocellular Carcinoma
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
- Trial name
- SIERRA (NCT05883644)
- Testing
- Durvalumab, Tremelimumab
- Where
- 40 sites in United States, France and 8 more
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Advanced Hepatocellular Carcinoma
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced…
- Trial name
- NCT04000737
- Testing
- Sorafenib+YIV-906
- Where
- 24 sites in United States, China and 2 more
- Volunteers
- 62 people
- Sponsor
- Yiviva Inc.
Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
The application of transarterial chemoembolisation (TACE) with drug-eluting beads in patients with hepatocellular carcinoma and its response to the treatment will be observed.
- Trial name
- NCT04780789
- Testing
- Transarterial Chemoembolization
- Volunteers
- 61 people
- Sponsor
- Brno University Hospital